DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Effectiveness of Tropisetron Plus Risperidone for Improving Cognitive and Perceptual Disturbances in Schizophrenia

Information source: Baylor College of Medicine
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Smoking Cessation; Schizophrenia

Intervention: Tropisetron (Drug); Placebo (Drug); Risperidone (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Baylor College of Medicine

Official(s) and/or principal investigator(s):
Thomas Kosten, MD, Principal Investigator, Affiliation: Baylor College of Medicine

Summary

This study will determine the effectiveness of tropisetron plus risperidone in improving cognitive symptoms in Chinese people with schizophrenia.

Clinical Details

Official title: Tropisetron With Risperidone for Schizophrenia

Study design: Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Cognition Domains

Detailed description: Schizophrenia is a chronic and disabling brain disorder. People with schizophrenia may experience hallucinations, delusions, disordered thinking, movement disorders, social withdrawal, and cognitive deficits. In considering the high rate of cigarette smoking among people with schizophrenia, it is also likely that they smoke. People with schizophrenia who smoke tend to experience improved cognition, and tobacco withdrawal has been associated with deterioration of cognition. This suggests that nicotine may improve cognitive deficits or medication side effects in people with schizophrenia. Auditory sensory gating, a neural mechanism thought to reflect sensory information processing and affect cognition, is diminished in people with schizophrenia. Auditory sensory gating has been associated with the 7 nicotinic acetylcholine receptor, a brain receptor that is important for cognition and can be activated by nicotine. Activation of this receptor using an agonist medication, such as tropisetron, may produce the same positive effect that nicotine has on cognition. This study will determine the effectiveness of using tropisetron as supplemental therapy to the atypical neuroleptic risperidone in people with schizophrenia. Participants in this 12-week double blind study will be randomly assigned to receive either tropisetron or placebo. All participants will also follow a 6-mg risperidone regimen. Study visits will occur every 2 weeks throughout the study and final outcome assessments will include cognitive functioning and treatment safety and effectiveness.

Eligibility

Minimum age: 18 Years. Maximum age: 64 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Currently resides in Beijing, China

- Diagnosis of schizophrenia or schizophreniform disorder

- Duration of symptoms is no longer than 60 months

- No history of treatment with antipsychotic medication or, if previously treated, a

total lifetime usage of less than 14 days

- Current psychotic symptoms are of moderate severity or greater as measured by one of

the five psychotic items in the Brief Psychiatric Rating Scale (BPRS) Exclusion Criteria:

- Diagnostic and Statistical Manual of Mental Disorders(DSM)-IV Axis I diagnosis other

than schizophrenia or schizophreniform psychosis

- Documented disease of the central nervous system that might interfere with the trial

assessments (e. g., stroke, tumor, Parkinson's disease, Huntington's disease, seizure disorder, history of brain trauma resulting in significant impairment, chronic infection)

- Acute, unstable, and/or significant and untreated medical illness (e. g., infection,

unstable diabetes, uncontrolled hypertension)

- A clinically significant echocardiogram (ECG) abnormality in the opinion of the

investigator

- Pregnant or breastfeeding

- Use of prohibited concomitant therapy

- History of severe allergy or hypersensitivity

- Dependence on alcohol or illegal drugs

- Use of any of the following medications during the trial: antipsychotic medications

other than risperidone; psychostimulants; or antidepressants

Locations and Contacts

Beijing Hui-Long Guan Hospital, Beijing, China

Baylor College of Medicine - Michael E. DeBakey VA Medical Center, Houston, Texas 77030, United States

Additional Information

Starting date: November 2006
Last updated: August 12, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017